Evidence map›Paper›PMID 28184178›Full record

ArticleCancer cell international2017

Effect of

Taijie Li, Weijuan Qin, Yanqiong Liu, Shan Li, Xue Qin, Zhiming Liu

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer cell international, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 2 pooled it
2.8field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 2 syntheses or guidelines pooled it, 39 citations in OpenAlex.

  1. Pooled it
  2. Association of RAGE rs1800625 Polymorphism and Cancer Risk: A Meta-Analysis of 18 Case-Control Studies.Medical science monitor : international medical journal of experimental and clinical research · 2019
    Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Association ofJournal of Cancer · 2019
    Article
  15. Review
  16. Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Taijie LiDepartment of Clinical Laboratory, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi China.
Weijuan QinDepartment of Clinical Laboratory, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi China.
Yanqiong LiuDepartment of Clinical Laboratory, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi China.
Shan LiDepartment of Clinical Laboratory, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi China.
Xue QinDepartment of Clinical Laboratory, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi China.
Zhiming LiuDepartment of General Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi China.
First Affiliated Hospital of GuangXi Medical University · CNGuangxi Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTo investigate the influence of polymorphisms in the receptor for advanced glycation end products (RAGE) gene and circulating soluble RAGE (sRAGE) levels on susceptibility to gastric cancer, and identify whether these polymorphisms were correlated with serum sRAGE levels.

methodsWe performed a hospital-based case-control study involving 200 gastric cancer patients and 207 cancer-free controls. Four well-characterized

resultsThe rs2070600 AG genotype might play a predominant role in the development of gastric cancer (adjusted OR 1.62, 95% CI 1.03-2.58). In contrast, the rs184003 GT genotype represented significantly reduced risk for gastric cancer (adjusted OR 0.62, 95% CI 0.39-0.99). Subgroup analysis demonstrated that rs2070600 AG variant genotype enhanced the gastric cancer risk among nonsmokers (OR 1.71, 95% CI 1.01-2.91), nondrinkers (OR 1.75, 95% CI 1.03-2.97), and patients with tumor stage III (OR 2.00, 95% CI 1.13-3.56). The average sRAGE levels in the gastric cancer patients were significantly decreased compared with those of the healthy controls. Subjects carrying the rs2070600 AG genotype had a decreased ability to produce sRAGE. Subjects carrying the rs184003 T variant allele had an increased ability to sRAGE.

conclusionsThese findings suggested that the variant genotypes of rs184003 and rs2070600 in the

Indexed as

Gastric cancerLevelsPolymorphismRAGEsRAGE

Identifiers

PMID28184178
PMCPMC5294806
OpenAlexW2587192173

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.